Figure A1 from Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial
Open Access
- 31 March 2023
- other
- Published by American Association for Cancer Research (AACR)